Clinical Trial

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Study acronym: CHARGE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Protocol Amendment History 5 changes
notable Trial sites expanded: 102 -> 144 locations 2026-08-01
notable Trial sites expanded: 30 -> 102 locations 2026-07-07
notable Trial sites expanded: 11 -> 30 locations 2026-06-06
critical Recruitment opened 2026-05-09
notable Trial sites expanded: 0 -> 11 locations 2026-05-09
Trial Details
NCT Number NCT07499232
Lead Sponsor Janssen Research & Development, LLC
Conditions Crohn Disease
Enrollment 530 participants
Start Date 2026-04-21
Primary Completion 2028-11-15 (estimated)
Study Completion 2030-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-31